Skip to main content

Table 3 Results of univariate and multivariate analyses of risk factors of acute nausea among 312 cases with palonosetron receiving MEC

From: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

  Univariate Multivariate
n OR 95% CI P-value OR 95% CI P-value
Age < 75 vs. ≥75 years 312 n.c.         
Sex Female (vs. Male) 312 1.162 0.510 , 2.647 0.720     
Anti-cancer drug 312          
 L-OHP 178 1.000   ref        
 CPT11 60 1.676 0.636 , 4.420 0.296      
 CBDCA 74 0.920 0.316 , 2.679 0.878      
Oral 5-FU 312          
 Nothing 157 1.000   ref        
 S-1 30 1.859 0.556 , 6.210 0.314      
 Capecitabine 125 0.938 0.382 , 2.301 0.888      
Additional oral steroid days 2 or 3 (vs. Nothing) 312 1.203 0.531 , 2.726 0.658     
NK1RA (vs. Nothing) 312 1.175 0.474 , 2.913 0.728     
Primary organ 312          
 colorectal cancer 211 1.000   ref        
 gastric cancer 25 n.c.          
 lung cancer 23 1.516 0.412 , 5.572 0.531      
 gynecological cancer 53 0.606 0.173 , 2.131 0.435      
Hb < 10 mg/dl 312 1.010 0.443 , 2.301 0.981     
Neut < 1500/μl 312 0.528 0.068 , 4.096 0.541     
PLT < 7.5 × 104/μl 312 1.078 0.473 , 2.457 0.858     
CRE ≥1.1 mg/dl 312 6.643 1.848 , 23.881 0.004 12.601 2.437 , 65.157 0.003
AST > 2.5 ULN 312 1.576 0.651 , 3.815 0.313     
ALT > 2.5 ULN 312 1.936 0.767 , 4.890 0.162     
Fever elevation > 38 °C 312 1.696 0.363 , 7.921 0.502     
Constipation 312 1.218 0.506 , 2.933 0.661     
Diarrhea 312 3.241 1.397 , 7.522 0.006 2.594 0.984 , 6.834 0.054
Oral mucositis 312 2.189 0.940 , 5.099 0.069     
Taste alteration 312 1.895 0.833 , 4.314 0.128     
Neuropathy 312 2.916 1.064 , 7.986 0.037 1.088 0.346 , 3.423 0.885
Eruption 312 3.630 1.470 , 8.965 0.005 2.012 0.716 , 5.657 0.185
General fatigue 312 4.085 1.492 , 11.180 0.006 3.728 1.098 , 12.661 0.035
NRS ≥1 312 1.406 0.598 , 3.309 0.435     
PS 312           
 0 155 1.000   ref    1.000   ref   
 1 146 3.435 1.215 , 9.708 0.020 2.568 0.820 , 8.043 0.105
 2 11 25.000 5.668 , 110.271 0.000 19.829 3.200 , 122.865 0.001
  1. MEC moderately emetogenic chemotherapy, L-OHP oxaliplatin, CPT-11 irinotecan, CBDCA carboplatin, Hb hemoglobin, Neut neutrophil, PLT platelet, CRE creatine, ULN upper limit of normal, NRS numerical rating scale, PS performance status, OR odds ratio, CI confidence interval